Alector Inc (ALEC) Stock Price, Quote & News

Company Profile

Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potent...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 231 5660

Website: www.alector.com

Address:

131 Oyster Point Boulevard, Suite 600, South San Francisco, United States

NivSadovsky May. 11 at 9:07 AM

$ALEC is entering a "death spiral." Following the total failure of its lead FTD program, the company is effectively a "zombie biotech" with nothing but early-stage assets. The real story is the $125M ATM offering filed under the radar. Selling $125M worth of stock at $2.00 will flood the market with 60M+ new shares. With the $2.00 psychological and regulatory support about to snap, the path of least resistance is heavily skewed to the downside. Short interest is likely to skyrocket as the market digests the magnitude of the dilution.

0 · Reply

revuelto May. 9 at 5:58 PM

$ALEC appears to be setting up for a strategic IP acquisition😀

0 · Reply

TeenageMutantNinjaTrader May. 5 at 12:10 AM

$ALEC jeff brown “timed stock” Anyone remember that scam artist a few years ago? What an idiot.

0 · Reply

LiveCommander Apr. 30 at 1:16 AM

$ALEC pulling the plug on PROGRESS-AD Phase 2 for nivisnebart after interim futility hit. Another progranulin shot at early Alzheimer's that just didn't move the needle. GSK partnership value takes a real hit here. Cash runway and FTD program $WVE become the whole story now. Brutal print 📉

0 · Reply

BillionerOfKing Apr. 29 at 11:12 PM

$ALEC Current Stock Price: $2.31 Contracts to trade: $2.5 ALEC May 15 2026 Call Entry: $0.05 Exit: $0.09 ROI: 85% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

focafoca99 Apr. 29 at 8:55 PM

$ALEC halted the Phase 2 PROGRESS-AD trial after an interim futility analysis said it was unlikely to meet its endpoint. https://www.rapidticker.com/news/alec-alector-to-discontinue-phase-2-1dc605

0 · Reply

ScoobaStevez Apr. 29 at 8:22 PM

$ALEC

0 · Reply

SuperGreenToday Apr. 27 at 3:33 PM

$ALEC Share Price: $2.44 Contract Selected: Oct 16, 2026 $0.5 Calls Buy Zone: $1.23 – $1.52 Target Zone: $2.17 – $2.65 Potential Upside: 66% ROI Time to Expiration: 171 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

manymore Apr. 22 at 5:55 PM

$ALEC interesting activity

0 · Reply

Pedrogs87 Apr. 22 at 5:51 PM

$ALEC

0 · Reply

Alector reports Q1 EPS (21c), consensus (28c)

May 7, 2026, 4:05 PM EDT - 6 days ago

Alector Reports First Quarter 2026 Financial Results and Provides Business Update

2026-05-04T12:24:23.000Z - 9 days ago

Alector price target raised to $2 from 90c at Morgan Stanley

2026-04-29T21:30:12.000Z - 14 days ago

Alector to discontinue PROGRESS-AD trial of nivisnebart

GSK

Apr 29, 2026, 4:05 PM EDT - 14 days ago

Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer's Disease Following Interim Futility Analysis

2026-04-15T11:05:35.000Z - 4 weeks ago

Alector upgraded to Overweight from Neutral at Cantor Fitzgerald

2026-03-12T20:20:11.000Z - 2 months ago

Alector files $400M mixed securities shelf

2026-03-10T09:50:11.000Z - 2 months ago

BTIG upgrades Alector to Buy on shift to novel therapeutics

2026-03-10T09:40:38.000Z - 2 months ago

Alector upgraded to Buy from Neutral at BTIG

Mar 3, 2026, 3:10 PM EST - 2 months ago

Alector Transcript: TD Cowen 46th Annual Health Care Conference

2026-02-25T22:05:49.000Z - 2 months ago

Alector reports Q4 EPS (34c), consensus (36c)

Feb 25, 2026, 4:05 PM EST - 2 months ago

Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 24, 2026, 8:00 AM EST - 2 months ago

Alector to Participate in the TD Cowen 46th Annual Health Care Conference

2026-01-08T12:44:56.000Z - 4 months ago

Alector price target raised to 90c from 75c at Morgan Stanley

2025-12-12T21:10:27.000Z - 5 months ago

Alector names Neil Berkley as CFO, Chief Business Officer

Dec 12, 2025, 4:05 PM EST - 5 months ago

Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer

Dec 8, 2025, 2:25 PM EST - 5 months ago

Alector Transcript: BofA Securities CNS Therapeutics Virtual Conference 2025

Dec 1, 2025, 4:05 PM EST - 5 months ago

Alector to Participate in the Bank of America CNS Therapeutics Conference

2025-11-17T12:41:29.000Z - 6 months ago

Alector price target lowered to 75c from $1.50 at Morgan Stanley

2025-11-06T23:25:43.000Z - 6 months ago

Alector reports Q3 EPS (34c), consensus (41c)

Nov 6, 2025, 4:05 PM EST - 6 months ago

Alector Reports Third Quarter 2025 Financial Results and Provides Business Update

2025-10-22T13:12:52.000Z - 7 months ago

Alector price target lowered to $5 from $10 at H.C. Wainwright

2025-10-22T09:40:16.000Z - 7 months ago

Alector downgraded to Neutral from Buy at BTIG

2025-10-22T09:20:10.000Z - 7 months ago

Alector downgraded to Market Perform from Outperform at William Blair

2025-10-22T08:45:27.000Z - 7 months ago

Alector downgraded to Neutral from Overweight at Cantor Fitzgerald

2025-10-22T08:40:15.000Z - 7 months ago

Alector downgraded to Neutral from Outperform at Mizuho

2025-10-22T08:40:10.000Z - 7 months ago

Alector downgraded to Hold from Buy at TD Cowen

2025-10-21T23:00:19.000Z - 7 months ago

Alector discontinues extension portion of INFRONT-3 trial

Oct 21, 2025, 6:45 PM EDT - 7 months ago

Alector Announces Results from its Phase 3 Clinical Trial of Potential FTD-GRN Therapeutic

Oct 21, 2025, 6:41 PM EDT - 7 months ago

Alector shares plunge after dementia drug fails to slow disease progression

Oct 21, 2025, 4:05 PM EDT - 7 months ago

Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update

Sep 22, 2025, 12:00 PM EDT - 8 months ago

Alector Transcript: Study Update

Sep 16, 2025, 8:00 AM EDT - 8 months ago

Alector to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier Programs

Sep 9, 2025, 1:30 PM EDT - 8 months ago

Alector Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 10:00 AM EDT - 8 months ago

Alector Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 4, 2025, 3:55 PM EDT - 8 months ago

Alector Transcript: Cantor Global Healthcare Conference 2025

Aug 28, 2025, 8:00 AM EDT - 9 months ago

Alector to Participate in Upcoming Healthcare Conferences

Aug 7, 2025, 4:30 PM EDT - 9 months ago

Alector Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:05 PM EDT - 9 months ago

Alector Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 4:05 PM EDT - 10 months ago

Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call

Jun 13, 2025, 4:05 PM EDT - 11 months ago

Alector Provides Executive Leadership Update

Jun 10, 2025, 8:40 AM EDT - 1 year ago

Alector Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 3, 2025, 8:00 AM EDT - 1 year ago

Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

May 20, 2025, 12:00 PM EDT - 1 year ago

Alector Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 13, 2025, 5:20 PM EDT - 1 year ago

Alector Transcript: BofA Securities 2025 Healthcare Conference

May 8, 2025, 4:05 PM EDT - 1 year ago

Alector Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease

GSK

Mar 18, 2025, 2:00 PM EDT - 1 year ago

Alector Transcript: Virtual CNS Forum

Mar 11, 2025, 8:40 AM EDT - 1 year ago

Alector Transcript: Leerink Global Healthcare Conference 2025

Mar 4, 2025, 9:10 AM EST - 1 year ago

Alector Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 26, 2025, 4:30 PM EST - 1 year ago

Alector Earnings Call Transcript: Q4 2024

Feb 26, 2025, 4:05 PM EST - 1 year ago

Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 19, 2025, 4:05 PM EST - 1 year ago

Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call

Jan 13, 2025, 8:00 AM EST - 1 year ago

Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025

Nov 25, 2024, 4:05 PM EST - 1 year ago

Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update

Nov 14, 2024, 4:05 PM EST - 1 year ago

Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital

Nov 6, 2024, 4:05 PM EST - 1 year ago

Alector Reports Third Quarter 2024 Financial Results and Provides Business Update

Sep 17, 2024, 9:45 AM EDT - 1 year ago

Alector Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 9, 2024, 10:00 AM EDT - 1 year ago

Alector Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 5, 2024, 7:45 AM EDT - 1 year ago

Alector Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 7, 2024, 4:30 PM EDT - 1 year ago

Alector Earnings Call Transcript: Q2 2024

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Alector Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Alector to Host Mid-Year Earnings Conference Call

Jul 28, 2024, 8:05 AM EDT - 1 year ago

Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)

Jul 23, 2024, 7:00 AM EDT - 1 year ago

Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024

Jun 27, 2024, 7:00 AM EDT - 2 years ago

Alector Transcript: H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Jun 18, 2024, 3:00 PM EDT - 2 years ago

Alector Transcript: Status Update

Jun 10, 2024, 1:20 PM EDT - 2 years ago

Alector Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 10, 2024, 7:00 AM EDT - 2 years ago

Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform

May 20, 2024, 11:00 AM EDT - 2 years ago

Alector Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 14, 2024, 11:55 AM EDT - 2 years ago

Alector Transcript: BofA Securities 2024 Health Care Conference

Mar 19, 2024, 11:30 AM EDT - 2 years ago

Alector Transcript: Stifel Virtual 2024 CNS Day

Mar 13, 2024, 2:05 PM EDT - 2 years ago

Alector Transcript: Barclays 26th Annual Global Healthcare Conference 2024

Mar 12, 2024, 10:40 AM EDT - 2 years ago

Alector Transcript: Leerink Partners Global Biopharma Conference 2024

Mar 5, 2024, 10:30 AM EST - 2 years ago

Alector Transcript: TD Cowen 44th Annual Health Care Conference 2024

Feb 27, 2024, 4:30 PM EST - 2 years ago

Alector Earnings Call Transcript: Q4 2023

Feb 27, 2024, 4:05 PM EST - 2 years ago

Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 20, 2024, 4:05 PM EST - 2 years ago

Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call

Feb 8, 2024, 7:00 AM EST - 2 years ago

Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer's Disease

Feb 7, 2024, 7:00 AM EST - 2 years ago

FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

Jan 19, 2024, 9:20 AM EST - 2 years ago

Alector Announces Closing of Public Offering

Jan 17, 2024, 8:54 AM EST - 2 years ago

Alector Announces Pricing of Public Offering of Common Stock

Jan 16, 2024, 4:01 PM EST - 2 years ago

Alector Announces Proposed Public Offering of Common Stock

Dec 13, 2023, 11:00 AM EST - 2 years ago

Alector Transcript: Status Update

Dec 7, 2023, 12:00 PM EST - 2 years ago

Alector Transcript: Status Update

Nov 28, 2023, 7:00 AM EST - 2 years ago

Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs

Nov 8, 2023, 7:00 AM EST - 2 years ago

Alector to Participate in the Stifel Healthcare Conference

Nov 7, 2023, 4:05 PM EST - 2 years ago

Alector Reports Third Quarter 2023 Financial Results and Provides Business Update

Oct 27, 2023, 7:00 AM EDT - 2 years ago

Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

Sep 11, 2023, 4:55 PM EDT - 2 years ago

Alector Transcript: Morgan Stanley 21st Annual Global Healthcare Conference 2023

Aug 3, 2023, 4:30 PM EDT - 3 years ago

Alector Earnings Call Transcript: Q2 2023

Jun 6, 2023, 7:00 AM EDT - 3 years ago

Alector to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

May 4, 2023, 4:05 PM EDT - 3 years ago

Alector Reports First Quarter 2023 Financial Results and Provides Business Update

May 2, 2023, 7:00 AM EDT - 3 years ago

Alector to Participate in the BofA Securities 2023 Healthcare Conference

Feb 28, 2023, 4:05 PM EST - 3 years ago

Alector Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Dec 8, 2022, 4:30 PM EST - 3 years ago

Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Nov 29, 2022, 11:05 AM EST - 3 years ago

Alector Presents Results from First-in-Human Phase 1 Study of AL101 for the Treatment of Neurodegenerative Diseases

Oct 13, 2022, 8:00 AM EDT - 3 years ago

Alector Announces Promotion of Clare Hunt to Chief People Officer

NivSadovsky May. 11 at 9:07 AM

0 · Reply

revuelto May. 9 at 5:58 PM

$ALEC appears to be setting up for a strategic IP acquisition😀

0 · Reply

TeenageMutantNinjaTrader May. 5 at 12:10 AM

$ALEC jeff brown “timed stock” Anyone remember that scam artist a few years ago? What an idiot.

0 · Reply

LiveCommander Apr. 30 at 1:16 AM

0 · Reply

BillionerOfKing Apr. 29 at 11:12 PM

0 · Reply

focafoca99 Apr. 29 at 8:55 PM

$ALEC halted the Phase 2 PROGRESS-AD trial after an interim futility analysis said it was unlikely to meet its endpoint. https://www.rapidticker.com/news/alec-alector-to-discontinue-phase-2-1dc605

0 · Reply

ScoobaStevez Apr. 29 at 8:22 PM

$ALEC

0 · Reply

SuperGreenToday Apr. 27 at 3:33 PM

0 · Reply

manymore Apr. 22 at 5:55 PM

$ALEC interesting activity

0 · Reply

Pedrogs87 Apr. 22 at 5:51 PM

$ALEC

0 · Reply

Pedrogs87 Apr. 16 at 9:28 AM

$ALEC https://seekingalpha.com/news/4575281-alector-stock-upgraded-cantor-fitzgerald

0 · Reply

revuelto Apr. 15 at 11:25 PM

$ALEC how high can it climb? 🎉

0 · Reply

GSP Apr. 7 at 9:32 PM

$PTON $ASTC $GVH $ALEC $BFRG

1 · Reply

GSP Apr. 7 at 9:30 PM

No video tonight, but here is what I'm watching tomorrow: $PTON $ASTC $GVH $ALEC $BFRG

0 · Reply

notreload_ai Mar. 10 at 2:24 PM

$ALEC $CLRB $DNTH $FSS $HIMS -- THE WSJ

0 · Reply

Nothere2023 Mar. 10 at 1:47 PM

$ALEC Hold

0 · Reply

Pedrogs87 Mar. 10 at 11:50 AM

$ALEC BTIG upgrades Alector with a $6.00 price target. Previous rating adjustments showed downgrades from multiple analysts. Today, Alector (ALEC) received a significant upgrade from BTIG analyst Thomas Shrader. Shrader has moved the rating from 'Neutral' to 'Buy', setting a new price target of $6.00. This change reflects renewed confidence in Alector's market position and potential growth.

0 · Reply

Pedrogs87 Mar. 10 at 11:48 AM

$ALEC https://www.investing.com/news/analyst-ratings/alector-stock-rating-upgraded-to-buy-at-btig-on-bbbshuttle-focus-93CH-4551550

0 · Reply

Nothere2023 Mar. 9 at 3:46 PM

$ALEC Break 2.5 for 3 💪👍🚀🚀

0 · Reply

Nothere2023 Mar. 9 at 2:57 PM

$ALEC rally starts

0 · Reply

Pedrogs87 Mar. 9 at 2:56 PM

$ALEC

0 · Reply

Nothere2023 Mar. 6 at 3:20 PM

$ALEC Tbis should rocket back by next week !! No worries Excellent set up !!

0 · Reply

Market Cap	227.60M
Revenue (ttm)	21.05M
Net Income (ttm)	-142.93M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-679.00%
Debt to Equity Ratio	0.94

Volume	459,000
Avg Vol	645,180
Day's Range	N/A - N/A
Shares Out	111.03M
Stochastic %K	22%
Beta	0.64
Analysts	Sell
Price Target	$3.10